Liquid Biopsi in Lung Cancer


  • Fasya Az Zahra Universitas Lampung
  • Zhafira Rima Wanjaya University of Lampung
  • Lucky T.H Hutapea



Diagnostic, liquid biopsy, lung cancer


Pulmonology intervention has experienced rapid progress, especially in diagnosing and treating lung cancer. Pulmonology intervention itself can be defined as the science and art related to the ability to perform invasive procedures in the field of pulmonology both for diagnostic and treatment needs and for this requires additional training beyond the existing standard training programs in the field of pulmonary diseases. Diagnostic and therapeutic procedures included in pulmonary interventions are transthoracic needle aspiration (TTNA), transbronchial needle aspiration (TBNA), rigid bronchoscopy, endobronchial ultrasonography (EBUS), laser bronchoscopy, electroendobronchial surgery, argon-plasma coagulation (APC), cryotherapy, airway stenting, balloon bronchoplasty, endobronchial radiation (brachytherapy), pleuroscopy (medical thoracoscopy), photodynamic therapy, percutaneous dilated tracheostomy, transtracheal oxygen indwelling and image-guided thoracic intervention. For nodules larger (>4 cm) and peripherally located, a CT-guided percutaneous approach with transthoracic needle aspiration (TTNA) showed high sensitivity and specificity of 90% and 97%, respectively. However, this procedure has a risk of causing a pneumothorax with an incidence that varies between 17% - 33%. Furthermore, if the size of the nodule is <1.5 cm, the success rate will be smaller, namely 74.4%. Likewise with mediastinoscopy which has been a standard procedure for determining the mediastinal stage in lung cancer, even though it shows a high sensitivity of up to >90%, but the risk of causing fatal complications is injury to the large blood vessels, nerves, trachea and bronchi and esophagus. (<0.5%) and complications of pneumothorax (2.5%).

Author Biography

Lucky T.H Hutapea




Daftar Pustaka

Duma N, Santana-Davila R, Molina JR. Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin. Proc. 2019. 94(1):1623–40.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021. 71(2). 209–249.

Osmani L, Askin F, Gabrielson E, Li QK. Current WHO Guidelines and the Critical Role of Immunohistochemical Markers inthe Subclassification of Non-Small Cell Lung Carcinoma (NSCLC). Moving from Targeted Therapy to Immunotherapy. Semin. Cancer Biol. 2018. 52(3). 103–109.

Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J. Thorac. Oncol. 2015. 10(2). 1240–42.

Nicholson AG, Tsao MS. Beasley MB. Borczuk AC. Brambilla E, Cooper WA, Dacic S, Jain D, Kerr KM, Lantuejoul S. The 2021 WHO Classification of Lung Tumors: Impact of Advances since 2015. J. Thorac. Oncol. 2021. 17(6). 362–87.

Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. J. Clin. Oncol. 2008. 26(1). 3552–59.

Alexander M, Kim SY, Cheng H. Update 2020: Management of Non-Small Cell Lung Cancer. Lung. 2020. 198(1). 897–907.

Yoneda K, Imanishi N, Ichiki Y, Tanaka F. Treatment of Non-Small Cell Lung Cancer with EGFR-Mutations. J. UOEH. 2019. 41(1). 153–163.

Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D’Amico TA. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2022. 20(1) 497–530.

Tong JH, Yeung SF, Chan AWH, Chung LY, Chau SL, Lung RWM, Tong CY, Chow C, Tin, EKY, Yu YH. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis. Clin. Cancer Res. 2016. 22(9). 3048–56.

Pruis MA, Geurts-Giele WRR, von der TJH, Meijssen IC, Dinjens WNM, Aerts JGJV, Dingemans AMC, Lolkema MP, Paats MS, Dubbink HJ. Highly Accurate DNA-Based Detection and Treatment Results of MET Exon 14 Skipping Mutations in Lung Cancer. Lung Cancer. 2020. 140(1). 46–54.

Bladt F. Friese-Hamim M. Ihling C. Wilm C. Blaukat A. The C-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models. Cancers. 2014. 6(2). 1736–52.

Bladt F, Faden B, Friese-Hamim M, Knuehl C, Wilm C, Fittschen C, Grädler U, Meyring M, Dorsch D, Jaehrling F. EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective C-Met Inhibitors. Clin. Cancer Res. 2011. 19. 2941–51.

Friese-Hamim M, Bladt F, Locatelli G, Stammberger U, Blaukat A. The Selective C-Met Inhibitor Tepotinib Can Overcome Epidermal Growth Factor Receptor Inhibitor Resistance Mediated by Aberrant c-Met Activation in NSCLC Models. Am. J. Cancer Res 2017. 7(3). 962–72.

Mikami K, Medová M, Nisa L, Francica P, Glück AA, Tschan MP, Blaukat A, Bladt F, Aebersold DM, Zimmer Y. Impact of P53 Status on Radiosensitization of Tumor Cells by MET Inhibition-Associated Checkpoint Abrogation. Mol. Cancer Res. 2015. 13(2). 1544–53.

Falchook GS, Kurzrock R, Amin HM, Xiong, W, Fu S, Piha-Paul SA, Janku F, Eskandari G, Catenacci DV, Klevesath M. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. Clin. Cancer Res. 2020. 26(1). 1237–46.

Drilon A, Clark JW, Weiss J, Ou SHI, Camidge DR, Solomon BJ, Otterson GA, Villaruz LC, Riely GJ, Heist RS. Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration. Nat. Med. 2020. 26(3). 47–51.

Pakkala S, Ramalingam SS. Personalized Therapy for Lung Cancer: Striking a Moving Target. JCI Insight 2018. 3. 120858.

Burke M. Rashdan S. Management of Immune‐Related Adverse Events in patients with non‐small cell lung Cancer. Front Oncol. 2021. 11. 720-59.

Li ZB, Chen DD, He QJ, Li L, Zhou G, Fu YM, et al. The LAC score indicates significant fibrosis in patients with chronic drug‐induced liver injury: a large biopsy‐based study. Front Pharmacol. 2021. 12. 734-90.



How to Cite

Az Zahra, F., Rima Wanjaya, Z., & T.H Hutapea, L. . (2023). Liquid Biopsi in Lung Cancer. Medical Profession Journal of Lampung, 13(5), 725-730.